Recently, Huawei is approved of sales of wrist ECG collector. Combined the technology with wearable device, new series of smart watch was launched and could be used for measuring blood pressure.

HTG Molecular Diagnostics reported after the close of the market on Thursday that its second quarter revenues bumped up about 5 percent year over year.

Lucira Health reported on Thursday after the close of the market that it had $12.4 million in revenues for the second quarter, the firm's second full quarter of commercial activity.

Aditxt, a Richmond, VA-based biotech company, has partnered with Great Lakes Medical Laboratory (GLML) to offer the AditxtScore for COVID-19 throughout Michigan. According to the company, the test is able to assess the strength of an individual's immune response to the virus.

Berkeley Lights reported on Tuesday an 82 percent increase in second quarter revenues driven by higher consumables and service revenues.

Tesis Labs and Personal Genome Diagnostics said Tuesday that they are collaborating to develop new genomic tests for cancer patients that combine somatic and germline variant results, with the goal of advancing market access and accelerating adoption of their products.

From January to the end of July 2021, Thermo Fisher Scientific has launched a more comprehensive strategic cooperation. with local Chinese institutions.

Oncocyte said after the close of the market on Tuesday that its revenues for the three months ended June 30 were $2 million, compared to $143,000 in the same period of 2020 and beating analysts' average estimate of $1.57 million.

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.

Qiagen and OncXerna Therapeutics said on Monday that they have signed a master agreement to develop a next-generation sequencing companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.

For many metastatic cancer patients, a one-time whole-genome analysis of a biopsy may be enough to identify their treatment options, a new study has found.

Castle Biosciences reported after the close of the market on Monday that its first quarter revenues rose 79 percent year over year, thanks to more than double the number of tests delivered during the quarter.

Quidel reported after the close of the market Thursday that its second quarter revenues fell 12 percent year over year, which the firm attributed to decreased demand for its Sofia and PCR COVID-19 assays, as well as lower demand for influenza products.

Meridian Bioscience reported on Friday morning a 25 percent year-over-year decline in its fiscal third quarter revenues, one year after recording record highs in Q3 2020.

A newly finalized guidance from the US Food and Drug Administration (FDA) helps manufacturers understand how to use near-infrared (NIR)-based analyses in evaluating drug attributes.